Table 1.
Characteristics of the patients
| Characteristic | Total population |
|---|---|
| Median (IQR) | |
| Age | 66 (61–76) |
| BMI | 26.1 (23.6–28.3) |
| N (%) | |
| Sex | |
| Male | 36 (61.0%) |
| Female | 23 (39.0%) |
| Type of cancer | |
| Lung cancer | 16 (27.1%) |
| Bladder cancer | 15 (25.4%) |
| Kidney cancer | 11 (18.6%) |
| Uterine cancer | 5 (8.5%) |
| Pancreatic cancer | 3 (5.1%) |
| Other | 8 (13.6%) |
| Missing | 1 (1.7%) |
| Type of therapy | |
| Anti-PD1 | 49 (83.0%) |
| Anti-PD-L1 | 8 (13.6%) |
| I/O combo | 2 (3.4%) |
| Vaccine | |
| BNT162b2 | 41 (69.5%) |
| AZD1222 | 15 (25.4%) |
| mRNA-1273 | 3 (5.1%) |
| Vaccine-related adverse events | |
| None | 37 (62.7%) |
| Fever | 1 (1.7%) |
| Pain at injection site | 11 (18.6%) |
| Fatigue | 3 (5.1%) |
| Other | 1 (1.7%) |
| Comorbidities | |
| Yes | 39 (66.1%) |
| None | 11 (18.6%) |
| Missing | 9 (15.3%) |
IQR interquartile range, BMI body mass index, I/O Immunotherapy